Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday

BioMarin Pharmaceutical (NASDAQ: BMRN) reported its third-quarter earnings after market close Monday, and they were good enough to push the biotech stock almost 2% higher the following day. With that performance, the shares notched a slight beat on the bellwether S&P 500 index, which ticked up by 1.2%. For the quarter, BioMarin's revenue came in at $776 million, which was 4% higher on a year-over-year basis. Net income not according to generally accepted accounting principles (GAAP), on the other hand, dived sharply by 88% to $22 million, or $0.12 per share. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool